Research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
=== Example: Azathioprine Therapy === Azathioprine is an immunomodulator for inflammatory bowel disease, for instance. Its metabolite relies on two different enzymes (TPMT and NUDT15) to eliminate its effect on our body during its metabolism. If the patient has the phenotype of the enzymes that metabolize it poorly, i.e., the poor metabolizer, more toxic metabolites are accumulated in the body. Thus, the patient has a greater risk of the related side-effect. The side effect causes the adjustment of dosage or switching to another drug.
=== Neural signals from the GI tract === One method that the brain uses to evaluate the contents of the gut is through vagal nerve fibers that carry signals between the brain and the gastrointestinal tract (GI tract). Stretch receptors work to inhibit appetite upon distention of the GI tract by sending signals along the vagus nerve afferent pathway and inhibiting the hunger center.
=== Hydrodynamic chromatography === Hydrodynamic chromatography (HDC) is derived from the observed phenomenon that large droplets move faster than small ones. In a column, this happens because the center of mass of larger droplets is prevented from being as close to the sides of the column as smaller droplets because of their larger overall size. Larger droplets will elute first from the middle of the column while smaller droplets stick to the sides of the column and elute last. This form of chromatography is useful for separating analytes by molar mass (or molecular mass), size, shape, and structure when used in conjunction with light scattering detectors, viscometers, and refractometers. The two main types of HDC are open tube and packed column. Open tube offers rapid separation times for small particles, whereas packed column HDC can increase resolution and is better suited for particles with an average molecular mass larger than
== Resistance genes == Resistance to blasticidin S can be conferred by either of two deaminases: BSD, originally isolated from Aspergillus terreus or bsr, isolated from Bacillus cereus. Both deaminases work by modifying blasticidin S directly, replacing the amine on the cytosine ring with a hydroxyl group, resulting in the inactive deaminohydroxy-blasticin S. bsr and BSD are the most commonly used resistance genes. The proteins produced from these genes enable the cells carrying them to produce proteins in the presence of blasticidin.
Sources: en.wikipedia.org
== Inhibitors == There are two types of inhibitor of PPO, those competitive to oxygen in the copper site of the enzyme and those competitive to phenolics. Tentoxin has also been used in recent research to eliminate the PPO activity from seedlings of higher plants. Tropolone is a grape polyphenol oxidase inhibitor. Another inhibitor of this enzyme is potassium metabisulfite. Banana root PPO activity is strongly inhibited by dithiothreitol and sodium metabisulfite, as is banana fruit PPO by similar sulfur-containing compounds including sodium dithionite and cysteine, in addition to ascorbic acid (vitamin C).
== Distribution coefficient and log D == The distribution coefficient, log D, is the ratio of the sum of the concentrations of all forms of the compound (ionized plus un-ionized) in each of the two phases, one essentially always aqueous; as such, it depends on the pH of the aqueous phase, and log D = log P for non-ionizable compounds at any pH. For measurements of distribution coefficients, the pH of the aqueous phase is buffered to a specific value such that the pH is not significantly perturbed by the introduction of the compound. The value of each log D is then determined as the logarithm of a ratio—of the sum of the experimentally measured concentrations of the solute's various forms in one solvent, to the sum of such concentrations of its forms in the other solvent; it can be expressed as
=== Geometrical factors === Successive stepwise formation constants Kn in a series such as MLn (n = 1, 2, ...) usually decrease as n increases. Exceptions to this rule occur when the geometry of the MLn complexes is not the same for all members of the series. The classic example is the formation of the diamminesilver(I) complex [Ag(NH3)2]+ in aqueous solution.
Sources: en.wikipedia.org
== Microbial adaptations == Survival in sea ice brine pockets and channels, which are freezing, hypersaline, and light-limited environments, requires organisms to adapt well to these conditions. Photosynthetic protists and cyanobacteria need to be able to produce energy through alternate metabolic pathways when light is limited within brine pockets. Sea ice brine pockets in Arctic and Antarctic sea ice sheets will experience several weeks of no light at certain locations. In addition to sea ice and snow blocking light from entering brine pockets, seasonal variations of light levels can result in brine pockets being extremely light-limited at times. Sea ice diatoms can alter their metabolic and photosynthetic pathways to survive during periods of little-to-no light. Such adaptations include developing flexible photosystems and altering photosynthetic pigment compositions to allow diatoms to photoacclimate and maintain high photosynthetic efficiency when light levels are low. Sea ice diatoms also have the ability to upregulate and downregulate proteins required for photosynthesis rapidly as light levels change, which helps them survive the environmental stresses of becoming trapped in sea ice and being released back into the ocean as ice melts. Additionally, sea ice microalgae (photosynthetic protists) may be mixotrophic, allowing them to switch to heterotrophy when light is limited.
Very few of our contributors believe that a "definitive" history of the Cold War is possible (or indeed that it should be possible). But a heterogeneous approach creates a strong need for contextualization. ... First and foremost we need to situate the Cold War within the wider history of the twentieth century in a global perspective. We need to indicate how Cold War conflicts connect to broader trends in social, economic, and intellectual history as well as to the political and military developments of the longer term of which it forms a part. Corresponding to the broader "emotional turn" in 21st century historiography, historians have increasingly begun to consider the unfolding of the Cold War in emotional and psychological terms. They have sought emotional explanations for political decisions and developments typically examined from a rational perspective and have analysed interpersonal dynamics between world leaders. Frank Costigliola is a prolific proponent of the role of emotion in historical analysis. For example, he positions the breakdown of the wartime alliance between the United States and the Soviet Union and the hostilities of the early Cold War as being, in part, a result of the heightened emotions of key figures in American foreign policy, like Averell Harriman, following the death of Franklin D. Roosevelt. To Costigliola, it was the "attitudes and rhetoric" of key diplomats at the end of World War II that set the tone for future relations between the United States and the Soviet Union.
=== Phase 1 === ABL-301 (SAR-446159) – bispecific antibody against α-synuclein [72] ALS-205 (PMX-205) – complement C5a receptor antagonist [73] ALX-001 (BMS-984923) – metabotropic glutamate mGlu5 receptor silent allosteric modulator [74] ARV-102 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [75] ATH-399A (DWP-307399; HL-192) – nuclear receptor subfamily 4 group A member 2 (NR4A2) agonist [76] CT-2500 – undefined mechanism of action [77] FB-418 – Bcr-Abl tyrosine kinase inhibitor and leucine-rich repeat kinase 2 (LRRK2) inhibitor [78] GT-02287 – β-glucocerebrosidase (GCase) activator and/or chaperone [79] HL-400 – NLR family pyrin domain containing 3 (NLRP3) inhibitor [80] HNC-364 (rasagiline prodrug) – monoamine oxidase B (MAO-B) inhibitor [81] Human amniotic epithelial cell therapy - Shanghai iCELL Biotechnology (hAECs; hAESCs) – cell replacement [82] JNJ-0376 – undefined mechanism of action [83] JX-2105 – undefined mechanism of action [84] Lu AF28996 (Lu AF-28996) – dopamine D1 and D2 receptor agonist [85] LY-3962681 – RNA interference and α-synuclein expression modulator [86] MEDI-1341 (TAK-341) – monoclonal antibody against α-synuclein [87] NEU-723 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [88] NN-9001 – undefined mechanism of action [89] PK-081 – α-synuclein degrader [90] Selnoflast (NLRP3i; RG-6418; RO-7486967; Somalix) – NLR family pyrin domain containing 3 (NLRP3) inhibitor inhibitor [91] TRN-501 – undefined mechanism of action [92] VQ-101 – glucosylceramidase stimulant [93] WID-2301 – undefined mechanism of action [94] WIT-2001 – undefined mechanism of action [95]
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.